https://orcid.org/0000-0002-4067-0709
References
- Inoshita N, Nishioka H. 2,3 The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathol 2018; 35:51–6.
- Micko ASG, Wöhrer A, Höftberger R, et al. 1 MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas Springer. Pituitary 2017; 20:643–53.
- Møller MW, Andersen MS, Pedersen CB, Kristensen BW, Poulsen FR. 1 Intraoperative low field MRI in transsphenoidapituitary surgery. Endocrine Connections 2018; 7:897–906.
- Glebauskiene B, Liutkeviciene R, Vilkeviciute A, et al. Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma HindawiBioMed Research InternationalVolume. Biomed Res Int 2018;2018:7490585.
- Foltran RK, Amorim PVGH, Duarte FH, et al. 1 Study of major genetic factors involved in pituitary tumorigenesis and their impact on clinical and biological characteristics of sporadic somatotropinomas and non-functioning pituitary adenomas. Braz J Med Biol Res 2018; 51:e7427
- Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activityand invasiveness among pituitary adenomas and carcinomas: ananalysis using the MIB-1 antibody. Neurosurgery 1996;38:99–107.
- Kennedy AL, Morton JP, Manoharan I, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011; 42:36–49.
- Kitz K, Knosp E, Koos WT, Korn A. Proliferation in pituitary adenomas: Measurement by MAb KI 67. Acta Neurochir Suppl (Wien) 1991;53:60–4.
- Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 1999;52:107–11.
- Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Mönting J, Reincke M. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 2003;99:674–9.
- Chang EF, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. JNS 2008;108:736–45.
- Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: What is new? Acta Neuropathol 2006;111:1–7.
- Bogdan Bălinişteanu1 High Ki-67 expression is associated with prolactin secreting pituitary adenomas. Bosn J Basic Med Sci 2017;17:104–8.
- Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sexrelated difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab 1997;82:2102–7.
- Ma W, Ikeda H, Yoshimoto T. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 2002;95:258–66.
- Paek K-II, Kim SH, Song SH, Choi SW, et al. Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci 2005;20:489–94.